Drug Profile

CX 621

Alternative Names: CX621

Latest Information Update: 03 Aug 2018

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator TiGenix
Class Anti-inflammatories; Stem cell therapies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

No development reported Autoimmune disorders

Most Recent Events

31 Jul 2018 TiGenix has been acquired by Takeda
28 Jul 2018 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in Spain (Intralymphatic, Injection)
20 Aug 2013 CX 621 is available for licensing as of 20 Aug 2013. www.tigenix.com

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com